Alnylam Pharmaceuticals, Inc. (ALNY)
155.94
-0.72
(-0.46%)
USD |
NASDAQ |
Nov 06, 16:00
156.25
+0.31
(+0.20%)
After-Hours: 20:00
Alnylam Pharmaceuticals Cash from Investing (Quarterly) : -311.74M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -311.74M |
| June 30, 2026 | -363.46M |
| March 31, 2026 | -25.54M |
| December 31, 2025 | -37.17M |
| September 30, 2025 | 501.11M |
| June 30, 2025 | -141.38M |
| March 31, 2025 | 113.77M |
| December 31, 2024 | -52.91M |
| September 30, 2024 | -30.25M |
| June 30, 2024 | 33.94M |
| March 31, 2024 | -67.62M |
| December 31, 2023 | -240.66M |
| September 30, 2023 | -10.76M |
| June 30, 2023 | -8.713M |
| March 31, 2023 | -76.22M |
| December 31, 2022 | -139.91M |
| September 30, 2022 | 313.89M |
| June 30, 2022 | 142.79M |
| March 31, 2022 | -147.42M |
| December 31, 2021 | -413.40M |
| September 30, 2021 | -88.27M |
| June 30, 2021 | 157.02M |
| March 31, 2021 | 71.35M |
| December 31, 2020 | -97.89M |
| September 30, 2020 | -10.09M |
| Date | Value |
|---|---|
| June 30, 2020 | -441.23M |
| March 31, 2020 | 113.69M |
| December 31, 2019 | -220.85M |
| September 30, 2019 | -10.08M |
| June 30, 2019 | -289.40M |
| March 31, 2019 | 102.65M |
| December 31, 2018 | 248.96M |
| September 30, 2018 | 96.17M |
| June 30, 2018 | 62.62M |
| March 31, 2018 | -134.81M |
| December 31, 2017 | -160.59M |
| September 30, 2017 | -137.18M |
| June 30, 2017 | -67.67M |
| March 31, 2017 | 75.08M |
| December 31, 2016 | 100.39M |
| September 30, 2016 | -31.40M |
| June 30, 2016 | -44.34M |
| March 31, 2016 | 117.94M |
| December 31, 2015 | 78.27M |
| September 30, 2015 | 48.67M |
| June 30, 2015 | -106.94M |
| March 31, 2015 | -341.33M |
| December 31, 2014 | 21.44M |
| September 30, 2014 | 37.91M |
| June 30, 2014 | -228.38M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 23.50M |
| Vertex Pharmaceuticals, Inc. | -6.101B |
| Pfizer Inc. | -2.026B |
| BridgeBio Pharma, Inc. | 36.61M |
| Cerenome, Inc. | 5.366M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 340.98M |
| Cash from Financing (Quarterly) | 18.35M |
| Free Cash Flow | 752.13M |
| Free Cash Flow Per Share (Quarterly) | 1.964 |
| Free Cash Flow to Equity (Quarterly) | 261.78M |
| Free Cash Flow to Firm (Quarterly) | 889.33M |
| Free Cash Flow Yield | 3.50% |